About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01853306

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib in Subjects With Solid Tumors

Study identifier: NCT01853306
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Metastatic or unresectable breast or ovarian cancer for which standard curative measures do not exist or are no longer effective (platinum-resistant ovarian cancer not permitted)
  • Must have documented deleterious BRCA1 or BRCA2 mutation
  • Three or fewer cytotoxic chemotherapy regimens

Type of study:

Phase I study

Treatment:

Participants are treated with one of three formulations of veliparib

Study sites:

Contact for all sites is:

Contact: Brian Oliver, BS 847-938-5570 brian.oliver@abbvie.com
Contact: Xenia Kovacs, BS 847-938-4057 xenia.kovacs@abbvie.com

Arizona
Scottsdale
Site Reference ID/Investigator# 89594

Michigan
Detroit
Site Reference ID/Investigator# 89593

New Jersey
Hackensack
Site Reference ID/Investigator# 89834

New Brunswick
Site Reference ID/Investigator# 89595

Utah
Salt Lake City
Site Reference ID/Investigator# 89596

Page updated 06/13/13

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org